Restrictive Intraoperative Fluid Rate is Associated with Improved Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

被引:5
|
作者
Peng, June S. [1 ,2 ]
LaPiano, Jessica [3 ]
Wang, Katy [4 ]
Attwood, Kristopher [4 ]
Skitzki, Joseph J. [5 ]
Kane, John M., III [1 ]
Francescutti, Valerie A. [1 ,5 ]
机构
[1] Roswell Pk Comprehens Canc Ctr, Dept Surg Oncol, Buffalo, NY 14203 USA
[2] Penn State Univ, Div Surg Oncol, Coll Med, Dept Surg, Hershey, PA 16801 USA
[3] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
[4] Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA
[5] McMaster Univ, Dept Surg, Hamilton, ON, Canada
关键词
MORBIDITY; THERAPY; TRIAL;
D O I
10.1245/s10434-021-10556-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Management of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) has historically favored liberal fluid administration owing to lengthy duration of surgery and hyperthermia. This practice has been challenged in recent years with studies demonstrating improved outcomes with restrictive fluid administration. Methods Patients who underwent CS/HIPEC between March 2010 and September 2018 were included for analysis. Patients who received an above-median fluid rate (high-IVF) versus below-median fluid rate (low-IVF) were compared, and multivariate analyses were performed for length of stay, 90-day unplanned readmissions, and major complications. Results The 167 patients had a mean age of 56.7 +/- 11.4 years and body mass index of 29.5 +/- 6.9 kg/m(2). The median rate of total intraoperative crystalloid and colloid was 7.4 mL/kg/h. The low-IVF group had less blood loss (183 vs. 330 mL, p = 0.002), were less likely to need intraoperative vasopressor drip (2.4% vs. 11.9%, p = 0.018), and experienced fewer cardiac complications (2.4% vs. 10.7%, p = 0.031), pneumonias (0% vs. 6.0%, p = 0.024), and Clavien-Dindo grade 3-5 complications (14.5% vs. 33.3%, p = 0.004). Multivariate analyses identified bowel resection (HR 4.65, p = 0.0008) as a risk factor for 90-day unplanned readmission, while bowel resection, intraoperative fluid rate, and estimated blood loss were associated with increased length of stay. Conclusion Higher intraoperative fluid intake was associated with multiple postoperative complications and increased length of stay, and represents a potentially avoidable risk factor for morbidity in CS/HIPEC.
引用
收藏
页码:163 / 173
页数:11
相关论文
共 50 条
  • [31] Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis
    Gammon, David C.
    Dutton, Traci
    Piperdi, Bilal
    Zybert, Jason
    Wolfe, Steven H.
    Nguyen, Erin
    Sbat, Dalia
    Pillarisetty, Venu G.
    Sullivan, Mary
    Whalen, Giles F.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (13) : 1186 - 1190
  • [32] Failure to rescue following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Li, Kevin Y.
    Mokdad, Ali A.
    Minter, Rebecca M.
    Mansour, John C.
    Choti, Michael A.
    Augustine, Mathew M.
    Polanco, Patricio M.
    JOURNAL OF SURGICAL RESEARCH, 2017, 214 : 209 - 215
  • [33] Predictors of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Paredes, Anghela Z.
    Abdel-Misih, Sherif
    Schmidt, Carl
    Dillhoff, Mary E.
    Pawlik, Timothy M.
    Cloyd, Jordan M.
    JOURNAL OF SURGICAL RESEARCH, 2019, 234 : 103 - 109
  • [34] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly is Safe and Effective
    Laks, Shachar
    Bilik, Alona
    Schtrechman, Gal
    Adileh, Mohammad
    Mor, Eyal
    Boursi, Ben
    Halpern, Naama
    Margalit, Ofer
    Shacham-Shmueli, Einat
    Nissan, Aviram
    Ben-Yaacov, Almog
    JOURNAL OF SURGICAL RESEARCH, 2022, 279 : 739 - 747
  • [35] Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis
    Martin, Alexander S.
    Abbott, Daniel E.
    Hanseman, Dennis
    Sussman, Jonathan E.
    Kenkel, Alexander
    Greiwe, Parker
    Saeed, Noor
    Ahmad, Samar H.
    Sussman, Jeffrey J.
    Ahmad, Syed A.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (06) : 1941 - 1947
  • [36] Cytoreductive Surgery with or Without Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Hepatocellular Carcinoma
    Tabrizian, Parissa
    Franssen, Bernardo
    Jibara, Ghalib
    Sweeney, Robert
    Sarpel, Umut
    Schwartz, Myron
    Labow, Daniel
    JOURNAL OF SURGICAL ONCOLOGY, 2014, 110 (07) : 786 - 790
  • [37] The management of goal-directed fluid therapy during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Tuncel, Zeliha
    Duzgun, Ozgul
    MEDICINE, 2024, 103 (20) : E38187
  • [38] Postoperative Respiratory Failure Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy is Associated with Volume of Intraoperative Crystalloid Administration and Worse Survival
    Pletcher, Eric
    Cha, Da Eun
    Gleeson, Elizabeth
    Shaltiel, Tali
    Magge, Deepa
    Sarpel, Umut
    Cohen, Noah
    Labow, Daniel
    Golas, Benjamin
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (01) : 437 - 444
  • [39] Impact of Concomitant Urologic Intervention on Clinical Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Saxena, Akshat
    Liauw, Winston
    Virk, Sohaib A.
    Morris, David L.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (10): : 943 - 948
  • [40] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Outcomes from a Single Tertiary Institution
    Tabrizian, Parissa
    Shrager, Brian
    Jibara, Ghalib
    Yang, Ming-Jim
    Romanoff, Anya
    Hiotis, Spiros
    Sarpel, Umut
    Labow, Daniel M.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2014, 18 (05) : 1024 - 1031